Annual report pursuant to Section 13 and 15(d)

Goodwill and Other Intangible Assets (Tables)

v3.20.1
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of December 31, 2019 and December 31, 2018 is as follows:

 

        As of
December 31, 2019		     As of
December 31, 2018		  
    Life   Carrying     Carrying  
    (Years)   Amount     Amount  
                 
Asuragen acquisition:                    
Thyroid   9   $ 8,519     $ 8,519  
RedPath acquisition:                    
Pancreas test   7     16,141       16,141  
Barrett’s test   9     18,351       18,351  
BioPharma acquisition:                    
Trademarks   10     1,600       -  
Customer relationships   8     5,700       -  
                     
CLIA Lab   2.3   $ 609     $ 609  
                     
Total       $ 50,920     $ 43,620  
                     
Accumulated Amortization       $ (17,419 )   $ (13,767 )
                     
Net Carrying Value       $ 33,501     $ 29,853  

Schedule of Goodwill Carrying Value

The following table displays a roll forward of the carrying amount of goodwill from January 1, 2018 to December 31, 2019:

 

    Carrying  
    Amount  
Balance as of January 1, 2018   $ -  
Balance as of December 31, 2018     -  
Goodwill acquired     8,273  
Adjustments     160  
Balance as of December 31, 2019   $ 8,433  

Schedule of Future Estimated Amortization Expense

Amortization expense was approximately $3.7 million and $3.3 million for the years ended December 31, 2019 and 2018, respectively. Estimated amortization expense for the next five years is as follows:

 

2020     2021     2022     2023     2024  
                           
$ 5,145     $ 5,781     $ 3,859     $ 3,859     $ 3,149